A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Thomas Jefferson University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
M.D. Anderson Cancer Center
Thomas Jefferson University
Massachusetts General Hospital
Thomas Jefferson University
Incyte Corporation
University of Miami
University of Maryland, Baltimore
University Health Network, Toronto
National Institutes of Health Clinical Center (CC)
PrECOG, LLC.
Celgene
SCRI Development Innovations, LLC
Thomas Jefferson University
Memorial Sloan Kettering Cancer Center
University of Washington
Incyte Corporation
Incyte Corporation
Fred Hutchinson Cancer Center
City of Hope Medical Center
Juno Therapeutics, a Subsidiary of Celgene
National Cancer Institute (NCI)
International Extranodal Lymphoma Study Group (IELSG)
National Cancer Institute (NCI)
University of Washington
Celgene
National Cancer Institute (NCI)
Astellas Pharma Inc
University of Miami
Bayer
Novartis
University College, London
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
Memorial Sloan Kettering Cancer Center
University of Nebraska
University of Nebraska
Juno Therapeutics, a Subsidiary of Celgene
Stanford University
National Institutes of Health Clinical Center (CC)
MorphoSys AG
Washington University School of Medicine
Sunnybrook Health Sciences Centre
University of Nebraska
University of Nebraska
M.D. Anderson Cancer Center